Cited by 163Bipolar Disorder and TreatmentSchizophrenia research and treatmentPersonality Disorders and Psychopathology

Stage managing bipolar disorder

Open access
Berk, Michael, Berk, Lesley, Dodd, Seetal, Cotton, Sue, Macneil, Craig, Daglas, Rothanthi, Conus, Philippe, Bechdolf, Andreas +2 more·2014·Bipolar Disorders

Abstract

Objectives: Clinical staging is widespread in medicine – it informs prognosis, clinical course, and treatment, and assists individualized care. Staging places an individual on a probabilistic continuum of increasing potential disease severity, ranging from clinically at‐risk or latency stage through first threshold episode of illness or recurrence, and, finally, to late or end‐stage disease. The aim of the present paper was to examine and update the evidence regarding staging in bipolar disorder, and how this might inform targeted and individualized intervention approaches. Methods: We provide a narrative review of the relevant information. Results: In bipolar disorder, the validity of staging is informed by a range of findings that accompany illness progression, including neuroimaging data suggesting incremental volume loss, cognitive changes, and a declining likelihood of response to pharmacological and psychosocial treatments. Staging informs the adoption of a number of approaches, including the active promotion of both indicated prevention for at‐risk individuals and early intervention strategies for newly diagnosed individuals, and the tailored implementation of treatments according to the stage of illness. Conclusions: The nature of bipolar disorder implies the presence of an active process of neuroprogression that is considered to be at least partly mediated by inflammation, oxidative stress, apoptosis, and changes in neurogenesis. It further supports the concept of neuroprotection, in that a diversity of agents have putative effects against these molecular targets. Clinically, staging suggests that the at‐risk state or first episode is a period that requires particularly active and broad‐based treatment, consistent with the hope that the temporal trajectory of the illness can be altered. Prompt treatment may be potentially neuroprotective and attenuate the neurostructural and neurocognitive changes that emerge with chronicity. Staging highlights the need for interventions at a service delivery level and implementing treatments at the earliest stage of illness possible.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bdi.12099

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The clinical staging model for psychosis is the most established, but similar models also emerged for bipolar, depressive and anxiety disorders.

    “The clinical staging model for psychosis is the most established 54,55 , but similar models also emerged for bipolar 56-59 , depressive 60,61 and anxiety 62-65 disorders.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Berk, M., Berk, L., Dodd, S., Cotton, S., Macneil, C., Daglas, R., Conus, P., Bechdolf, A., Moylan, S., & Malhi, G. S.
Affiliations
  • Deakin University (AU)
  • Orygen Youth Health (AU)
  • The University of Melbourne (AU)
  • Centre Hospitalier Universitaire Vaudois (CH)
  • University of Cologne (DE)
  • The University of Sydney (AU)
Corresponding author
Berk, Michael
Venue
Bipolar Disorders
Publisher
Wiley
Published
2013-06-20
Volume
16
Issue
5
Pages
471-477
ISSN
  • 1398-5647 (ISSN-L)
  • 1399-5618
OpenAlex
W2088159914
Cited by
163
References
47
Citations by year
2026: 3 · 2025: 5 · 2024: 10 · 2023: 6 · 2022: 6 · 2021: 10 · 2020: 14 · 2019: 11 · 2018: 19 · 2017: 14 · 2016: 15 · 2015: 32 · 2014: 16 · 2013: 2
FWCI
2.96
Type
journal article
Language
en
Open access
Locations
  • Bipolar Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • IRIS (submittedVersion)
  • Deakin Research Online (Deakin University) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • SERVAL (Université de Lausanne) (submittedVersion, other-oa)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Geelong Region Medical Research Foundation
  • National Alliance for Research on Schizophrenia and Depression
  • Beyond Blue
  • Deutsche Forschungsgemeinschaft
  • Bundesministerium für Bildung und Forschung
  • Universität zu Köln
  • Servier
  • H. Lundbeck A/S
  • National Health and Medical Research Council
  • Cilag
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
Keywords
bipolar disorder, clinical staging, neuroprogression, neuroprotection, first episode, illness trajectory, neuroimaging, cognitive decline, treatment response, early intervention, prevention, neuroinflammation, oxidative stress, apoptosis, neurogenesis
MeSH terms
Bipolar Disorder, Humans, Prognosis, Disease Progression, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review